Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients
Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients
Recruiting · NCT07210047 · Registry updated 2026-09-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 / Phase 2 | 2026-09-18 | NCT07210047 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| HuniLife Biotechnology, Inc. | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Far Eastern Memorial Hospital | Taipei | Taiwan | 1 |